Menu
Search
|

Menu

Close
X

Loxo Oncology Inc LOXO.OQ (NASDAQ Stock Exchange Global Market)

104.80 USD
-0.17 (-0.16%)
As of Feb 16
chart
Previous Close 104.97
Open 104.70
Volume 48,331
3m Avg Volume 150,277
Today’s High 105.69
Today’s Low 103.79
52 Week High 108.50
52 Week Low 40.01
Shares Outstanding (mil) 29.94
Market Capitalization (mil) 3,137.45
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.38 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-4.553
FY16
-3.445
FY15
-2.107
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
--
8.57
Price to Book (MRQ)
vs sector
7.96
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
-56.64
13.54
Return on Equity (TTM)
vs sector
-56.64
14.80

EXECUTIVE LEADERSHIP

Joshua Bilenker
President, Chief Executive Officer, Director, Since 2013
Salary: $492,500.00
Bonus: --
Jennifer Burstein
Vice President - Finance, Since 2015
Salary: $300,000.00
Bonus: --
Jacob Van Naarden
Chief Business Officer, Since 2014
Salary: $336,000.00
Bonus: --
Keith Flaherty
Director, Since 2013
Salary: --
Bonus: --
Lori Kunkel
Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

281 Tresser Blvd Fl 9
STAMFORD   CT   06901-3238

Phone: +1203.6533880

Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.

SPONSORED STORIES